Discovering Dermatology Times: April 2024
Learn more about the in-depth topics covered in the April 2024 print issue of Dermatology Times.
Learn more about the in-depth topics covered in the April 2024 print issue of Dermatology Times.
The 2024 AAD Innovation Academy meeting is scheduled to take place August 1-4, in Seattle, Washington. Discover the latest research and innovations across a broad…
A recent survey conducted by the American Academy of Dermatology (AAD) highlighted the heightened risk of sunburn and skin cancer faced by outdoor workers in…
In a comparison of pediatric dermatologists versus AI, dermatologists primarily exhibited greater performance.
Is basal cell carcinoma on the vermilion lip a distinctly rare phenomenon, sparsely documented in existing literature?
Sunday, June 2, 2024 | 6:45 pm – 8:15 pm CT Supported by an independent educational grant from Takeda Pharmaceuticals, Inc. Join us in Chicago…
Mark Lebwohl, MD, and Saakshi Khattri, MD, discuss the evolving landscape of plaque psoriasis treatments over the past year.
A 5-expert panel continues their conversation on atopic dermatitis, exploring beyond steroids and addressing unmet needs.
This case series describes the clinical features, antifungal susceptibility, and genome sequencing of Trichophyton indotineae in 11 patients in New York City.
Last week, the FDA approved an sBLA for Sandoz’s adalimumab-adaz in various strengths, including 10 mg/0.1 mL, 20 mg/0.2 mL, and 80 mg/0.8 mL.
Muscle spasms are the most common adverse event experienced by patients treated with hedgehog inhibitors for basal cell carcinomas.